Compare Stocks → War Over Taiwan? Protect Your Wealth NOW (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AXLANASDAQ:AYLANASDAQ:DBVTNASDAQ:GNFTNASDAQ:LOGC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXLAAxcella Health$0.40-8.9%$0.84$0.34▼$41.25$1.18M0.46267,009 shs6,700 shsAYLAAyala Pharmaceuticals$0.50$0.48$0.36▼$7.31$7.46M1.9876,300 shsN/ADBVTDBV Technologies$0.67-2.7%$0.78$0.65▼$2.37$129.42M0.7549,705 shs12,440 shsGNFTGenfit$3.45$3.58$2.89▼$4.75$171.91M1.0814,707 shs1,223 shsLOGCLogicBio Therapeutics$2.07$2.06$0.26▼$3.77$68.23M4.61652,526 shsN/A7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXLAAxcella Health0.00%0.00%0.00%0.00%-96.27%AYLAAyala Pharmaceuticals0.00%0.00%0.00%0.00%0.00%DBVTDBV Technologies+3.68%-0.09%-11.19%-22.97%-56.64%GNFTGenfit+0.15%0.00%-1.99%-9.92%-6.76%LOGCLogicBio Therapeutics0.00%0.00%0.00%0.00%0.00%War Over Taiwan? Protect Your Wealth NOW (Ad)With tensions rapidly escalating, Taiwan could provide the spark at any moment. Don't let your financial future get caught in the crossfire unprepared.Access my report now >>>MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXLAAxcella HealthN/AN/AN/AN/AN/AN/AN/AN/AAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ADBVTDBV Technologies2.2315 of 5 stars3.23.00.00.00.03.31.3GNFTGenfit0.7006 of 5 stars3.52.00.00.00.60.00.0LOGCLogicBio TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXLAAxcella HealthN/AN/AN/AN/AAYLAAyala PharmaceuticalsN/AN/AN/AN/ADBVTDBV Technologies2.33Hold$5.00645.16% UpsideGNFTGenfit3.00Buy$11.00218.84% UpsideLOGCLogicBio TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsLatest LOGC, AYLA, AXLA, GNFT, and DBVT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/5/2024GNFTGenfitHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.002/21/2024DBVTDBV TechnologiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXLAAxcella HealthN/AN/AN/AN/A$1.42 per shareN/AAYLAAyala Pharmaceuticals$3.51M2.13N/AN/A$2.45 per share0.21DBVTDBV Technologies$15.73M8.23N/AN/A$0.73 per share0.92GNFTGenfit$41.31M4.16N/AN/A$1.48 per share2.33LOGCLogicBio Therapeutics$5.41M12.61N/AN/A$0.48 per share4.31Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXLAAxcella Health-$81.19M-$19.25N/A∞N/AN/AN/A-259.91%N/AAYLAAyala Pharmaceuticals-$40.25M-$2.52N/AN/AN/A-2,341.69%-182.13%-139.83%N/ADBVTDBV Technologies-$72.73M-$0.39N/AN/AN/A-461.32%-46.33%-35.32%5/2/2024 (Estimated)GNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/A7/4/2024 (Estimated)LOGCLogicBio Therapeutics-$40.03M-$0.81N/AN/AN/A-246.71%-115.29%-53.01%N/ALatest LOGC, AYLA, AXLA, GNFT, and DBVT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/7/2024Q4 2023DBVTDBV Technologies-$0.16-$0.06+$0.10-$0.06$1.10 million$8.88 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXLAAxcella HealthN/AN/AN/AN/AN/AAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/ADBVTDBV TechnologiesN/AN/AN/AN/AN/AGNFTGenfitN/AN/AN/AN/AN/ALOGCLogicBio TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXLAAxcella HealthN/A0.800.80AYLAAyala PharmaceuticalsN/A2.282.28DBVTDBV TechnologiesN/A4.264.26GNFTGenfit0.922.942.94LOGCLogicBio Therapeutics0.171.992.26OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXLAAxcella Health65.07%AYLAAyala Pharmaceuticals22.10%DBVTDBV Technologies71.74%GNFTGenfit2.24%LOGCLogicBio Therapeutics39.11%Insider OwnershipCompanyInsider OwnershipAXLAAxcella Health2.20%AYLAAyala Pharmaceuticals3.60%DBVTDBV Technologies0.71%GNFTGenfit4.20%LOGCLogicBio Therapeutics8.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAXLAAxcella Health112.95 million2.88 millionOptionableAYLAAyala Pharmaceuticals3514.82 million14.29 millionNot OptionableDBVTDBV Technologies104192.87 million191.50 millionOptionableGNFTGenfit15949.83 million47.74 millionNot OptionableLOGCLogicBio Therapeutics6232.96 million30.29 millionNot OptionableLOGC, AYLA, AXLA, GNFT, and DBVT HeadlinesSourceHeadlineRVVTF Revive Therapeutics Ltd.seekingalpha.com - March 27 at 7:29 AMLogicBio's IPO: What You Need To Knowfinance.yahoo.com - September 24 at 9:29 AMRare Diseases Market is projected to grow at a CAGR of 12.27% by 2033: Visiongain Reports Ltduk.finance.yahoo.com - March 31 at 7:12 PMAlexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeuticsfinance.yahoo.com - November 16 at 5:21 PMLogicBio Therapeutics, Inc.: LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updatesfinanznachrichten.de - November 14 at 2:54 PMLogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updatesfinance.yahoo.com - November 14 at 9:53 AMShort Volatility Alert: LogicBio Therapeutics, Inc.benzinga.com - November 7 at 6:30 PMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SMBC, BTRS, LOGC, RCORkentuckytoday.com - October 23 at 11:01 AMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LOGC, IMRA, SBTXmarketwatch.com - October 17 at 10:54 PMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LOGC, FCRD, IMRAbignewsnetwork.com - October 16 at 4:39 PMAlexion, AstraZeneca Rare Disease to Acquire LogicBio Therapeuticsfinsmes.com - October 4 at 8:38 PMINVESTOR ALERT: The M&A Class Action Firm Announces the Investigation of LogicBio Therapeutics, Inc. - LOGCbenzinga.com - October 4 at 10:37 AMLooking Into LogicBio Therapeutics's Recent Short Interestmsn.com - October 3 at 7:50 PMLogicBio Therapeutics Shares Soar on Takeover by AstraZeneca >LOGCmarketwatch.com - October 3 at 2:49 PMAstraZeneca acquires local startup at 660% premiumbizjournals.com - October 3 at 2:49 PMLogicBio's stock skyrockets after buyout bid for a 667% premiumfinance.yahoo.com - October 3 at 2:49 PMAstraZeneca pays 660% premium for gene therapy firm LogicBiomsn.com - October 3 at 9:48 AMLogicBio To Be Bought By Alexion, AstraZeneca Rare Diseasenasdaq.com - October 3 at 9:48 AMAstraZeneca to Buy LogicBio Therapeutics for $68 Million >LOGCmarketwatch.com - October 3 at 9:48 AMWhy LogicBio Therapeutics Stock Is Soaring Todaymsn.com - October 3 at 9:48 AMAlexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicinefinance.yahoo.com - October 3 at 9:48 AMLogicBio® Therapeutics Announces Pre-Clinical Results for mLB-001 Published in Peer-reviewed Journal PLOS ONEfinance.yahoo.com - September 21 at 10:19 AMLogicBio Therapeutics Increuters.com - September 1 at 12:36 PMEarnings Update: LogicBio Therapeutics, Inc. (NASDAQ:LOGC) Just Reported And Analysts Are Boosting Their Estimatesfinance.yahoo.com - August 18 at 11:11 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAxcella HealthNASDAQ:AXLAAxcella Health Inc. operates as a clinical-stage biotechnology company in the United States. The company treats complex diseases using endogenous metabolic modulators. Its product pipeline includes AXA1125 that is in Phase 2a clinical trial for long COVID therapy for patients, as well as Phase 2b clinical trial for treating non-alcoholic steatohepatitis; and AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts.Ayala PharmaceuticalsNASDAQ:AYLAAyala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.DBV TechnologiesNASDAQ:DBVTDBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.GenfitNASDAQ:GNFTGenfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.LogicBio TherapeuticsNASDAQ:LOGCLogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.